JP2002529494A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002529494A5 JP2002529494A5 JP2000582018A JP2000582018A JP2002529494A5 JP 2002529494 A5 JP2002529494 A5 JP 2002529494A5 JP 2000582018 A JP2000582018 A JP 2000582018A JP 2000582018 A JP2000582018 A JP 2000582018A JP 2002529494 A5 JP2002529494 A5 JP 2002529494A5
- Authority
- JP
- Japan
- Prior art keywords
- mixture
- progesterone
- micronized progesterone
- tablet
- lubricant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 64
- 239000000203 mixture Substances 0.000 description 48
- 229960001207 micronized progesterone Drugs 0.000 description 32
- 239000003826 tablet Substances 0.000 description 29
- 238000002156 mixing Methods 0.000 description 23
- 239000000314 lubricant Substances 0.000 description 19
- 229960003387 progesterone Drugs 0.000 description 16
- 239000000186 progesterone Substances 0.000 description 16
- 239000004604 Blowing Agent Substances 0.000 description 14
- 238000007873 sieving Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 239000000945 filler Substances 0.000 description 11
- 239000004088 foaming agent Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000011148 porous material Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- YUSCRGFYKCAQHE-HQFNMCNFSA-N (8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;(8r,9s,13s,14s,16r,17r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 YUSCRGFYKCAQHE-HQFNMCNFSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- 229910002019 Aerosil® 380 Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 239000000003 vaginal tablet Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL127129 | 1998-11-18 | ||
| IL12712998A IL127129A (en) | 1998-11-18 | 1998-11-18 | Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared |
| PCT/IL1999/000619 WO2000028970A1 (en) | 1998-11-18 | 1999-11-17 | Vaginally administrable progesterone-containing tablets and method for preparing same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010223566A Division JP2011026335A (ja) | 1998-11-18 | 2010-10-01 | プロゲステロン含有経膣投与用錠剤およびその調製法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002529494A JP2002529494A (ja) | 2002-09-10 |
| JP2002529494A5 true JP2002529494A5 (enExample) | 2010-12-02 |
| JP4667601B2 JP4667601B2 (ja) | 2011-04-13 |
Family
ID=11072154
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000582018A Expired - Lifetime JP4667601B2 (ja) | 1998-11-18 | 1999-11-17 | プロゲステロン含有経膣投与用錠剤およびその調製法 |
| JP2010223566A Pending JP2011026335A (ja) | 1998-11-18 | 2010-10-01 | プロゲステロン含有経膣投与用錠剤およびその調製法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010223566A Pending JP2011026335A (ja) | 1998-11-18 | 2010-10-01 | プロゲステロン含有経膣投与用錠剤およびその調製法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US7300664B1 (enExample) |
| EP (2) | EP2386291A1 (enExample) |
| JP (2) | JP4667601B2 (enExample) |
| AU (1) | AU1176200A (enExample) |
| DK (1) | DK1131052T3 (enExample) |
| ES (1) | ES2390959T3 (enExample) |
| IL (1) | IL127129A (enExample) |
| WO (1) | WO2000028970A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL127129A (en) * | 1998-11-18 | 2004-06-01 | Ferring Bv | Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared |
| FR2821555B1 (fr) * | 2001-03-01 | 2003-05-16 | Besins Int Lab | Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations |
| KR20050084445A (ko) * | 2002-12-20 | 2005-08-26 | 다이노젠 파마세우티컬스, 인코포레이티드 | α₂δ 서브유닛 칼슘 채널 모듈레이터를 이용한 무통증방광 질환의 치료방법 |
| ES2275229T3 (es) * | 2003-03-21 | 2007-06-01 | Dynogen Pharmaceuticals, Inc. | Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio. |
| DE10316583A1 (de) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| US8828981B2 (en) | 2007-02-06 | 2014-09-09 | George Creasy | Progesterone for the treatment or prevention of spontaneous preterm birth |
| CA2744906A1 (en) * | 2007-11-29 | 2009-06-04 | Gregg A. Jackson | Progesterone-containing compositions and devices |
| US9107696B2 (en) | 2008-08-06 | 2015-08-18 | Emory University | Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus |
| WO2011073995A2 (en) | 2009-12-14 | 2011-06-23 | Lincoln Pharmaceuticals Limited | Liquid vaginal spray of progesterone |
| FR2997627B1 (fr) * | 2012-11-08 | 2015-01-16 | Hra Pharma Lab | Produit de co-micronisation comprenant de l'ulipristal acetate |
| CN114129530A (zh) * | 2021-12-08 | 2022-03-04 | 南京康川济医药科技有限公司 | 一种黄体酮缓释组合物及其制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3121663A (en) | 1956-02-09 | 1964-02-18 | Plough Lab Inc | Carbon dioxide releasing laxative suppository |
| US4252787A (en) * | 1976-12-27 | 1981-02-24 | Cambridge Research And Development Group | Anti-fertility composition and method |
| US4310510A (en) * | 1976-12-27 | 1982-01-12 | Sherman Kenneth N | Self administrable anti-fertility composition |
| US4187286A (en) * | 1979-01-02 | 1980-02-05 | G&W Laboratories, Inc. | Contraceptive suppository |
| US4322399A (en) * | 1979-10-19 | 1982-03-30 | Ortho Pharmaceutical Corporation | Vaginal suppository |
| JPS58152809A (ja) * | 1982-03-05 | 1983-09-10 | Eisai Co Ltd | 安定な発泡性「膣」坐剤 |
| US4583211A (en) * | 1982-06-15 | 1986-04-15 | Tokyo Shibaura Denki Kabushiki Kaisha | Frequency detecting circuit for digital information reproducing system |
| JPS6165822A (ja) * | 1984-09-06 | 1986-04-04 | Kao Corp | 月経困難症治療用膣投与剤 |
| US5116619A (en) * | 1988-08-30 | 1992-05-26 | Lee Roy Morgan | Vaginal progesterone tablet |
| US5084277A (en) * | 1988-08-30 | 1992-01-28 | Greco John C | Vaginal progesterone tablet |
| DK95093D0 (da) * | 1993-08-20 | 1993-08-20 | Novo Nordisk As | Farmaceutisk formulering indeholdende et hormon |
| US5543150A (en) * | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
| CH689802A5 (de) * | 1995-01-16 | 1999-11-30 | Grapha Holding Ag | Einrichtung zur Vereinzelung von stapelweise zugeführten flachen Gegenständen. |
| US5804277A (en) * | 1995-11-30 | 1998-09-08 | The United States Of America As Represented By The Secretary Of The Air Force | Three-dimensional fiber weave with cubic symmetry and no zero valued shear moduli |
| US5958455A (en) * | 1996-02-09 | 1999-09-28 | Quadrant Holdings Cambridge Ltd | Oral solid dosage forms, methods of making same and compositions thereof |
| US5837861A (en) * | 1997-02-10 | 1998-11-17 | Inspire Pharmaceuticals, Inc. | Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency |
| US6096291A (en) * | 1996-12-27 | 2000-08-01 | Biovector Therapeutics, S.A. | Mucosal administration of substances to mammals |
| US5993856A (en) | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
| US6306914B1 (en) * | 1997-10-21 | 2001-10-23 | Columbia Laboratories, Inc. | Progestin therapy for maintaining amenorrhea |
| NZ330596A (en) * | 1998-06-05 | 2001-02-23 | Dec Res | Intravaginal devices allowing for increased uptake of active ingredients |
| FR2772617B1 (fr) | 1997-12-19 | 2001-03-09 | Besins Iscovesco Lab | Comprime de progesterone et son procede de preparation |
| FR2777784B1 (fr) * | 1998-04-27 | 2004-03-19 | Arepa | Composition pharmaceutique a base d'estrogene et de progesterone |
| IL127129A (en) * | 1998-11-18 | 2004-06-01 | Ferring Bv | Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared |
| US20070178139A1 (en) * | 1998-11-18 | 2007-08-02 | Yankov Vladimir I | Vaginally administratable progesterone-containing tablets and method for preparing same |
| DE102012021570A1 (de) * | 2012-11-02 | 2014-05-22 | Merck Patent Gmbh | Eu-aktivierte Leuchtstoffe |
-
1998
- 1998-11-18 IL IL12712998A patent/IL127129A/en not_active IP Right Cessation
-
1999
- 1999-11-17 WO PCT/IL1999/000619 patent/WO2000028970A1/en not_active Ceased
- 1999-11-17 JP JP2000582018A patent/JP4667601B2/ja not_active Expired - Lifetime
- 1999-11-17 EP EP11166346A patent/EP2386291A1/en not_active Ceased
- 1999-11-17 US US09/856,417 patent/US7300664B1/en not_active Expired - Lifetime
- 1999-11-17 DK DK99972096.4T patent/DK1131052T3/da active
- 1999-11-17 EP EP99972096A patent/EP1131052B1/en not_active Expired - Lifetime
- 1999-11-17 ES ES99972096T patent/ES2390959T3/es not_active Expired - Lifetime
- 1999-11-17 AU AU11762/00A patent/AU1176200A/en not_active Abandoned
-
2004
- 2004-04-26 US US10/832,742 patent/US7393543B2/en not_active Expired - Lifetime
-
2005
- 2005-01-12 US US11/039,062 patent/US7320800B2/en not_active Expired - Lifetime
-
2006
- 2006-04-20 US US11/408,614 patent/US20060188571A1/en not_active Abandoned
-
2010
- 2010-10-01 JP JP2010223566A patent/JP2011026335A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024201228B2 (en) | Orodispersible dosage unit containing an estetrol component | |
| US10660903B2 (en) | Orodispersible dosage unit containing an estetrol component | |
| JP2011026335A (ja) | プロゲステロン含有経膣投与用錠剤およびその調製法 | |
| JP2002529494A5 (enExample) | ||
| FI89455C (fi) | Foerfarande foer framstaellning av en farmaceutisk komposition | |
| CN111588699B (zh) | 一种含有达那唑的药物组合物及其应用 | |
| TWI239249B (en) | Vaginally administrable progesterone-containing tablets and method for preparing same | |
| HK1254650B (en) | Orodispersible dosage unit containing an estetrol component | |
| OA18501A (en) | Orodispersible dosage unit containing an estetrol component. |